- Home
- ACET vs CVM Comparison
ACET vs CVM Comparison
Compare ACET & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- CVM
- Stock Information
- Founded
- ACET 1947
- CVM 1983
- Country
- ACET United States
- CVM United States
- Employees
- ACET N/A
- CVM N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACET Health Care
- CVM Health Care
- Exchange
- ACET Nasdaq
- CVM Nasdaq
- Market Cap
- ACET 69.9M
- CVM 63.3M
- IPO Year
- ACET N/A
- CVM 1987
- Fundamental
- Price
- ACET $0.99
- CVM $8.91
- Analyst Decision
- ACET Buy
- CVM
- Analyst Count
- ACET 4
- CVM 0
- Target Price
- ACET $6.00
- CVM N/A
- AVG Volume (30 Days)
- ACET 2.6M
- CVM 82.9K
- Earning Date
- ACET 11-05-2025
- CVM 08-14-2025
- Dividend Yield
- ACET N/A
- CVM N/A
- EPS Growth
- ACET N/A
- CVM N/A
- EPS
- ACET N/A
- CVM N/A
- Revenue
- ACET N/A
- CVM N/A
- Revenue This Year
- ACET N/A
- CVM N/A
- Revenue Next Year
- ACET N/A
- CVM N/A
- P/E Ratio
- ACET N/A
- CVM N/A
- Revenue Growth
- ACET N/A
- CVM N/A
- 52 Week Low
- ACET $0.45
- CVM $1.98
- 52 Week High
- ACET $1.54
- CVM $32.70
- Technical
- Relative Strength Index (RSI)
- ACET 59.49
- CVM 44.54
- Support Level
- ACET $0.90
- CVM $9.37
- Resistance Level
- ACET $1.07
- CVM $10.24
- Average True Range (ATR)
- ACET 0.10
- CVM 0.69
- MACD
- ACET 0.01
- CVM -0.10
- Stochastic Oscillator
- ACET 65.71
- CVM 13.51
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.